Johnson & Johnson
Organization details
- Legal name
- Johnson & Johnson
- Former names
- Johnson & Johnson et AL
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- New Jersey
- Headquarters city
- New Brunswick
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- January
- Ticker symbol
- JNJ
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000200406
- EIN
- 22-1024240
- Wikidata ID
- Q333718
Board of directors
-
A. Eugene Washington · DirectorSince 2023
-
Alex Gorsky · DirectorSince 2023
-
Anne M. Mulcahy · DirectorSince 2023
-
D. Scott Davis · DirectorSince 2023
-
Daniel E. Pinto · DirectorSince 2025
-
Darius Adamczyk · DirectorSince 2023
-
Eugene A. Woods · DirectorSince 2023
-
Hubert Joly · DirectorSince 2023
-
Jennifer A. Doudna · DirectorSince 2023
-
Joaquin Duato · Director · CEO and Chairman of the BoardSince 2023
- Since 2025
-
Marillyn A. Hewson · DirectorSince 2023
-
Mark A. Weinberger · DirectorSince 2023
-
Mark B. McClellan · DirectorSince 2023
-
Mary C. Beckerle · DirectorSince 2023
-
Nadja West · DirectorSince 2023
-
Paula A. Johnson · DirectorSince 2023
Chief executives
Solid · grade C
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 50% of the scoring weight is on file.
- Dividends 15%
- 68
- Revenue growth 20%
- 60
- Earnings growth 15%
- 76
dividend grew 5.3% a year
4.6% a year in revenue
9.1% a year in earnings per share
50% of the scoring weight is on file. Figures cover January 2022 – December 2025.
Director election results
Annual meeting of April 23, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.1%
-
95.7%
-
96.4%
-
96.8%
-
97.5%
-
98.7%
-
98.7%
-
98.8%
-
99.0%
-
99.1%
-
99.1%
-
99.4%
Board connections
15 of this board's directors also sit on 26 other boards. 3 are in the same sector.
- via D. Scott Davis and Darius Adamczyk
- via Alex Gorsky and Mark A. Weinberger
- via Jennifer A. Doudna and Nadja West
- via Mark B. McClellan
- via Alex Gorsky
- via Eugene A. Woods
- via Marillyn A. Hewson
-
Exelixis Inc. Same sectorvia Mary C. Beckerle
- via John G. Morikis
- via John G. Morikis
- via Anne M. Mulcahy
- via D. Scott Davis
- via Mary C. Beckerle
- via Daniel E. Pinto
- via Alex Gorsky
- via Anne M. Mulcahy
-
Maze Therapeutics Inc. Same sectorvia Paula A. Johnson
- via Mark A. Weinberger
- via Nadja West
- via Hubert Joly
- via Hubert Joly
-
Tenet Healthcare Corporation Same sectorvia Nadja West
- via Mark B. McClellan
- via John G. Morikis
- via John G. Morikis
- via John G. Morikis
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $257,688
- 1 purchase by 1 insider
- Sold, last 12 months
- $150,667,572
- 28 sales by 10 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Schmid Timothy Officer (EVP, WW Chair, MedTech) | Option exercise | +11,070 | $131.94 | $1,460,576 |
| Sep 2, 2026 | Schmid Timothy Officer (EVP, WW Chair, MedTech) | Open-market sale | −11,070 | $274.74 | $3,041,372 |
| Sep 2, 2026 | Schmid Timothy Officer (EVP, WW Chair, MedTech) | Option exercise | +22,527 | $151.41 | $3,410,813 |
| Sep 2, 2026 | Schmid Timothy Officer (EVP, WW Chair, MedTech) | Open-market sale | −22,527 | $274.74 | $6,189,068 |
| Aug 17, 2026 | Jennifer L. Taubert Officer (EVP, WWC. Innovative Medicine) | Option exercise | +15,000 | $115.67 | $1,735,050 |
| Aug 17, 2026 | Jennifer L. Taubert Officer (EVP, WWC. Innovative Medicine) | Open-market sale | −15,000 | $263.36 | $3,950,400 |
| Aug 13, 2026 | Joaquin Duato Director, Officer (CEO and Chairman of the Board) | Option exercise | +123,291 | $115.67 | $14,261,070 |
| Aug 13, 2026 | Joaquin Duato Director, Officer (CEO and Chairman of the Board) | Open-market sale | −20,976 | $262.00 | $5,495,712 |
| Aug 13, 2026 | Joaquin Duato Director, Officer (CEO and Chairman of the Board) | Open-market sale | −102,315 | $261.00 | $26,704,215 |
| Aug 6, 2026 | Forminard Elizabeth Officer (EVP, Chief Legal Officer) | Option exercise | +9,344 | $131.94 | $1,232,847 |
| Aug 6, 2026 | Forminard Elizabeth Officer (EVP, Chief Legal Officer) | Open-market sale | −9,344 | $257.76 | $2,408,509 |
| Aug 6, 2026 | Forminard Elizabeth Officer (EVP, Chief Legal Officer) | Open-market sale | −6,574 | $255.93 | $1,682,484 |
| Aug 5, 2026 | Joaquin Duato Director, Officer (CEO and Chairman of the Board) | Open-market sale | −41,957 | $258.06 | $10,827,423 |
| Aug 5, 2026 | Joaquin Duato Director, Officer (CEO and Chairman of the Board) | Open-market sale | −6,523 | $258.74 | $1,687,761 |
| Jul 20, 2026 | Vanessa Broadhurst Officer (EVP, Global Corp Affairs) | Option exercise | +11,129 | $129.51 | $1,441,317 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Johnson & Johnson
Who is the CEO of Johnson & Johnson?
Joaquin Duato has been Johnson & Johnson's CEO and Chairman of the Board since January 2022.
How many directors are on Johnson & Johnson's board?
Johnson & Johnson's board has 17 directors: A. Eugene Washington, Alex Gorsky, Anne M. Mulcahy, D. Scott Davis, Daniel E. Pinto, Darius Adamczyk, Eugene A. Woods, Hubert Joly, Jennifer A. Doudna, Joaquin Duato and 7 others.
Are Johnson & Johnson insiders buying or selling shares?
Over the last 12 months, Johnson & Johnson insiders bought $257,688 of shares in 1 purchase and sold $150.7 million of shares in 28 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="johnson-johnson"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.